Treatment of C. difficile Toxin B Gene Positive Result

Immediate Management Steps

The American College of Gastroenterology recommends stopping the inciting antibiotic agent(s) immediately if clinically feasible, as continued antibiotic use significantly increases CDI recurrence risk 3, 4, 5
The Infectious Diseases Society of America suggests switching to agents less frequently associated with CDI, such as parenteral aminoglycosides, sulfonamides, macrolides, vancomycin, or tetracycline/tigecycline, if ongoing antibiotic therapy is required for another infection 3, 4
The Society for Healthcare Epidemiology of America recommends discontinuing proton pump inhibitors if not medically necessary, though evidence for this intervention remains limited 3, 5, 2
The American College of Emergency Physicians advises avoiding antimotility agents and opiates, as they may precipitate toxic megacolon 1, 2, 6

The American College of Gastroenterology defines non-severe CDI by a white blood cell count ≤15,000 cells/mL, serum creatinine <1.5 mg/dL, stool frequency <4 times daily, and no signs of severe colitis 1, 2, 6
The Infectious Diseases Society of America characterizes severe CDI by any of the following: white blood cell count ≥15,000 cells/mL, serum creatinine >1.5 mg/dL, fever >38.5°C with rigors, hemodynamic instability or septic shock, signs of peritonitis or ileus, elevated serum lactate, pseudomembranous colitis on endoscopy, or colonic distension or wall thickening on imaging 1, 2, 6

The American College of Gastroenterology recommends oral vancomycin 125 mg four times daily for 10 days or oral fidaxomicin 200 mg twice daily for 10 days as first-line therapy for non-severe CDI, with treatment selection based on disease severity assessment 1, 2, 6
The Infectious Diseases Society of America suggests oral vancomycin 125 mg four times daily for 10 days as primary recommendation for severe CDI 3, 5, 2, 6
The Society for Healthcare Epidemiology of America recommends oral fidaxomicin 200 mg twice daily for 10 days as an alternative for severe CDI 3, 5

The American College of Gastroenterology recommends treating the first recurrence the same as the initial episode based on severity, with metronidazole for non-severe CDI (if vancomycin/fidaxomicin unavailable) and vancomycin for severe CDI 7, 1, 6
The Infectious Diseases Society of America suggests oral vancomycin 125 mg four times daily for at least 10 days, with consideration of a taper/pulse strategy, for second and subsequent recurrences 7, 2, 6

The American College of Gastroenterology recommends bezlotoxumab (monoclonal antibody against toxin B) to prevent recurrences, particularly in patients with CDI due to the 027 epidemic strain, immunocompromised patients, and patients with severe CDI 3, 5, 1, 7, 4

The Centers for Disease Control and Prevention recommends placing patients in private rooms with dedicated toilet facilities when possible, using contact precautions with gown and gloves, and performing hand hygiene with soap and water (not alcohol-based sanitizers) 3
The Society for Healthcare Epidemiology of America suggests environmental cleaning with sporicidal disinfectants 3

The American College of Gastroenterology advises against using parenteral vancomycin for CDI, as it is not excreted into the colon and is ineffective 6
The Infectious Diseases Society of America recommends against performing "test of cure" after treatment, as clinical improvement is the primary measure of success 7
The Society for Healthcare Epidemiology of America suggests against delaying surgery in severe cases waiting for antibiotic response, as early colectomy improves outcomes in fulminant disease 6
The American College of Emergency Physicians advises against using metronidazole for severe CDI or for repeated courses due to inferior efficacy and neurotoxicity risk 4, 1